# nature communications

Matters arising

# Reply to: The G protein preference of orexin receptors is currently an unresolved issue

Received: 15 January 2023	Jie Yin <sup>1,6,7</sup> , Yanyong Kang <sup>2,7</sup> , Aaron P. McGrath <sup>2,7</sup> , Karen Chapman <sup>1</sup> , Megan Sjodt <sup>2</sup> , Eiji Kimura <sup>3</sup> , Atsutoshi Okabe <sup>3</sup> , Tatsuki Koike <sup>3</sup> , Yuhei Miyanohana <sup>3</sup> , Yuji Shimizu <sup>3</sup> , Rameshu Rallabandi <sup>4</sup> , Peng Lian <sup>5</sup> , Xiaochen Bai <sup>1</sup> , Mack Flinspach <sup>2</sup> ⊠, Jef K. De Brabander <sup>4</sup> ⊠ & Daniel M. Rosenbaum <sup>1,4</sup> ⊠
Accepted: 15 May 2023	
Published online: 01 June 2023	
Check for updates	
	REPLYING TO J. P. Kukkonen Nature Communications https://doi.org/10.1038/

s41467-023-38764-3 (2023)

Kukkonen challenges our interpretation of data in Figure 5d of our paper<sup>1</sup>. In this experiment, we co-transfected HEK293 cells with CMVdriven overexpression plasmids for OX<sub>2</sub>R *and* G<sub>αi1</sub> along with a pGlo-Sensor cAMP reporter construct, and measured diminished cAMP levels with OX<sub>2</sub>R agonists after forskolin stimulation. Results from this experiment showed a weak reduction in cAMP, without a characteristic low-nanomolar EC<sub>50</sub> for either TAK-925 or Orexin B (in contrast to the parallel inositol phosphate accumulation assay with overexpressed  $OX_2R$  and  $G_{\alpha q}$ ). We acknowledge the validity of Kukkonen's arguments that the cAMP data could also be explained by a combination of signaling through different G protein subtypes and/or regulation by PDEs. We also appreciate his arguments that the G protein selectivity or promiscuity exhibited by  $OX_2R$  will depend on the cell line and experimental setup, and has not been definitively established in CNS neurons.

## Reference

 Yin, J. et al. Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun 13, 2902 (2022).

## Acknowledgements

Portions of the original research were supported by the National Institutes of Health (R01NS097594 to J.K.D.B. and D.M.R.; R35GM116387 to D.M.R.), the Welch Foundation (I-1422 to J.K.D.B.; I-1770 to D.M.R.; I-1944 to X.B.), the Edward Mallinckrodt, Jr. Foundation (Scholar Award to D.M.R.), and the Julie and Louis Beecherl, Jr., Chair in Medical Science at The University of Texas Southwestern (to J.K.D.B.). The original OX2RmGsqiN cryo-EM data were collected at The University of Texas Southwestern Medical Center Cryo-EM Facility, which is funded by the CPRIT Core Facility Support Award RP170644.

#### Author contributions

J.Y., Y.K., M.F., J.K.D.B., and D.M.R. designed the original research. J.Y., Y.K., K.C., Y.S., R.R., and P.L. performed experiments. J.Y., Y.K., A.P.M., K.C., E.K., A.O., T.K., Y.M., Y.S., R.R., P.L., X.B., J.K.D.B., and D.M.R. analyzed data. J.Y., Y.K., A.P.M., M.S., J.K.D.B., T.K., M.F., and D.M.R. wrote the original paper. Authors from The University of Texas Southwestern Medical Center (J.Y., K.M., R.R., P.L., X.B., J.K.D.B., D.M.R.) obtained structural data for OX2R-mGsqiN bound to TAK-925. Authors from Takeda Pharmaceutical Company Limited (Y.K., A.P.M., M.S., E.K., A.O., T.K., Y.M., Y.S., M.F.) obtained structural data for OX2R-Gi1 bound to TAK-925. All authors contributed to this reply.

#### **Competing interests**

J.Y., K.C., R.R., P.L., X.B., J.K.D.B., and D.M.R. declare no competing interests. Y.K., A.P.M., M.S., E.K., A.O., T.K., Y.M., Y.S., and M.F. are current or former employees of Takeda Phamaceutical Company Limited.

#### **Additional information**

**Correspondence** and requests for materials should be addressed to Mack Flinspach, Jef K. De Brabander or Daniel M. Rosenbaum.

**Peer review information** *Nature Communications* thanks the anonymous reviewers for their contribution to the peer review of this work.

**Reprints and permissions information** is available at http://www.nature.com/reprints

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<sup>1</sup>Department of Biophysics, The University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX 75390, USA. <sup>2</sup>Takeda Development Center Americas, Inc., 9625 Towne Centre Drive, San Diego, CA 92121, USA. <sup>3</sup>Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. <sup>4</sup>Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. <sup>5</sup>BioHPC at the Lyda Hill Department of Bioinformatics, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. <sup>6</sup>Present address: Chinese Institute for Brain Research, No. 26 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing, China. <sup>7</sup>These authors contributed equally: Jie Yin, Yanyong Kang, Aaron P. McGrath. 🖂 e-mail: mflinspach@gmail.com; jef.debrabander@utsouthwestern.edu; dan.rosenbaum@utsouthwestern.edu **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/.

© The Author(s) 2023